Approved indications

• Adults with moderately to severely active rheumatoid arthritis (used with methotrexate).
• Adults with active psoriatic arthritis, alone or with methotrexate.
• Adults with active ankylosing spondylitis.
• Adults and pediatric patients weighing at least 15 kg with moderately to severely active ulcerative colitis.

Off-label uses

• Clinicians may sometimes use golimumab off-label for other inflammatory arthritides or autoimmune conditions where TNF blockers are helpful; however, evidence is usually limited to small studies or case reports, and other TNF inhibitors with specific approvals are often preferred.
• Because of the boxed warning for serious infections and malignancy, off-label use is generally reserved for situations where standard approved therapies have not worked or are not appropriate.

Efficacy expectations

• For rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, many patients notice improvement in joint pain and stiffness within about 4 to 12 weeks, with continued gains over several months.
• For ulcerative colitis, response is typically assessed after the induction dosing period (through about week 6); some patients achieve fewer bowel movements, less bleeding, and mucosal healing, while others may need additional or alternative therapy.
• Overall, Simponi provides symptom control and remission rates broadly comparable to other TNF inhibitors, with the potential convenience of once-monthly or every-4-week injections depending on the condition.

Typical dosing by condition

• Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (adults): 50 mg injected subcutaneously once a month; for rheumatoid arthritis it is used with methotrexate, while for psoriatic arthritis and ankylosing spondylitis it may be used with or without methotrexate or other nonbiologic DMARDs.
• Ulcerative colitis (adults and children ≥15 kg): weight-based induction at week 0 and week 2 (higher doses for patients ≥40 kg than for those 15 to <40 kg), followed by maintenance injections every 4 weeks at the same dose used at week 6.

How to take the medicine

• Simponi is given as a subcutaneous injection into the thigh, abdomen (avoiding the 2-inch area around the navel), or back of the upper arm (arm only if injected by someone else).
• Food does not affect Simponi because it is injected, so it can be taken with or without meals, generally at about the same time and date each dosing month.
• Adult patients may use either the prefilled syringe or SmartJect autoinjector; trained adults and children 12 years and older may self-inject with the prefilled syringe if their clinician agrees.

Special dosing instructions

• Before the injection, take the syringe or autoinjector out of the refrigerator and let it reach room temperature for at least 30 minutes; do not warm it in hot water, a microwave, or direct sunlight.
• Inspect the solution through the viewing window; do not use it if it is cloudy, discolored, or contains large particles.
• Rotate injection sites and avoid areas that are tender, bruised, red, hardened, or scarred.

Missed dose and overdose

• Missed dose: if a dose is missed, inject it as soon as you remember, then resume injections on the regular monthly or every-4-week schedule from that new date; do not give two full doses at the same time to make up for a missed dose.
• Overdose: if more than the prescribed amount is injected or multiple doses are given too close together, contact the prescriber, poison control center, or emergency services; there is no specific antidote, so management focuses on monitoring for side effects or infections and providing supportive care.

Common side effects

• Upper respiratory infections (such as colds), sore throat, and nasal congestion are among the most common effects and are usually mild.
• Injection site reactions (redness, itching, pain, or swelling where the medicine is injected) occur in a minority of patients and are typically mild to moderate and short-lived.
• Headache and low-grade fever are reported more often in children treated for ulcerative colitis and may occur at any time during treatment.

Serious or rare adverse effects

• Serious infections (including tuberculosis, invasive fungal infections, sepsis, and other opportunistic infections) can occur and may be life-threatening; symptoms like persistent fever, cough, shortness of breath, weight loss, night sweats, or warm, red, painful skin need urgent medical attention.
• New cancers, including lymphoma, skin cancers, and other malignancies, have been reported with TNF blockers, especially in children, adolescents, and young adults; new or changing skin lesions or unexplained lumps should be evaluated promptly.
• Worsening or new-onset heart failure, certain blood disorders (low blood counts), demyelinating diseases (similar to multiple sclerosis), severe liver injury, or serious allergic reactions including anaphylaxis are uncommon but serious and require immediate medical care if symptoms arise.

Warnings and precautions

• People with active infections should not start Simponi; all patients should be screened for latent tuberculosis and hepatitis B before treatment and monitored during and after therapy.
• Caution is advised in patients with a history of recurrent or chronic infections, heart failure, demyelinating disease, hepatitis, or prior malignancy.
• Pregnancy: available human data do not show a clear increase in birth defects, but the drug crosses the placenta, especially in the third trimester, and may affect the infant’s immune response; decisions about use in pregnancy are individualized.
• Breastfeeding: it is unknown how much golimumab passes into human milk or affects a nursing infant, so the benefits of breastfeeding should be weighed against the mother’s need for treatment.
• Use for ulcerative colitis is established only in adults and children who weigh at least 15 kg; safety and effectiveness in younger or smaller children, or in pediatric patients for arthritis indications, are not established for the subcutaneous formulation.

Relative safety compared with similar drugs

• Simponi shares class risks with other TNF inhibitors (serious infections, malignancy, autoimmune and neurologic events) and overall has a broadly similar safety profile to agents like adalimumab and infliximab.
• Its once-monthly or every-4-week dosing means fewer injections, which may reduce local injection reactions but does not eliminate systemic risks.

Reporting side effects and safety updates

• Patients should promptly report side effects to their healthcare provider, who can determine whether to adjust or stop treatment.
• Side effects can also be reported directly to the FDA MedWatch program (online or by phone) or to the manufacturer’s safety line listed in the Medication Guide, where ongoing safety information and updates are collected.

Drug and biologic interactions

• Using Simponi together with other biologic immunosuppressants approved for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis (such as other TNF blockers, abatacept, anakinra, or rituximab) increases infection risk and is not recommended.
• Simponi may normalize liver enzymes affected by inflammation and thereby alter blood levels of medicines with a narrow therapeutic range (for example, warfarin, cyclosporine, or theophylline); dose adjustment and closer monitoring may be needed when starting or stopping Simponi.

Vaccines, foods, alcohol, and supplements

• Live vaccines (such as certain measles, mumps, rubella, varicella, or intranasal flu vaccines) and therapeutic infectious agents should not be given during treatment; infants exposed in utero should generally avoid live vaccines for 6 months after the mother’s last dose.
• Inactivated (non-live) vaccines are usually acceptable and are recommended to be up to date before starting therapy, but responses may be somewhat reduced.
• No specific food interactions are known, and Simponi does not require dietary restrictions, though limiting alcohol is sensible in patients with liver disease or those taking other hepatotoxic drugs.
• Herbal and over-the-counter supplements that affect immune function (for example, high-dose echinacea or immune stimulants) should be used cautiously and only after discussion with a clinician.

Conditions and co-medications requiring caution

• Current serious infection, untreated latent or active tuberculosis, or active hepatitis B are key contraindications or reasons to delay therapy until adequately treated.
• Caution is needed in people with a history of recurrent infections, chronic lung disease, diabetes, HIV or other causes of immunosuppression, congestive heart failure, demyelinating disease, prior malignancy, or liver disease.
• Concomitant use of other immunosuppressive drugs (such as high-dose corticosteroids or certain chemotherapy agents) may further increase infection risk and requires individualized risk–benefit assessment.

Monitoring needs

• Before starting Simponi, patients should be evaluated for tuberculosis (risk assessment plus TB testing), hepatitis B infection, and have baseline laboratory studies as appropriate.
• During treatment, periodic clinical assessments plus labs such as complete blood count and liver enzymes are often obtained to monitor for cytopenias, liver injury, and other adverse effects, particularly in those on concomitant hepatotoxic or myelosuppressive drugs.
• Ongoing monitoring for signs of infection, new neurologic symptoms, heart failure symptoms, or skin changes suggestive of malignancy is important throughout therapy and for some time after discontinuation.

Q: How long does it take for Simponi to start working?
A: Many people feel some improvement in joint pain, stiffness, or bowel symptoms within 4 to 12 weeks of starting Simponi, but full benefits can take several months and vary by person and condition.

Q: Is Simponi the same as Simponi Aria?
A: Both medicines contain golimumab, but Simponi is given as a subcutaneous injection, while Simponi Aria is an intravenous infusion with different dosing schedules and approved uses.

Q: Can I stay on Simponi long term?
A: Many patients use Simponi for years when it remains effective and well tolerated, with regular monitoring for infections, cancers, and other potential side effects to ensure ongoing safety.

Q: Can I get vaccines while taking Simponi?
A: Most inactivated vaccines can be given, and it is best to be up to date on vaccines before starting Simponi, but live vaccines should generally be avoided during treatment and for a period afterward; your provider will plan an appropriate vaccine schedule.

Q: What should I do if I develop a fever or feel very unwell while on Simponi?
A: Contact your healthcare provider promptly if you develop fever, chills, cough, shortness of breath, severe fatigue, or other signs of infection, and seek urgent care if symptoms are severe, as Simponi can increase the risk of serious infections.

Storage

• Keep Simponi refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect it from light; do not freeze or shake it.
• If needed, it may be stored at room temperature (up to 77°F / 25°C) for one single period of up to 30 days in the carton, then must be used or thrown away and not returned to the refrigerator.
• Before injecting, allow the syringe or autoinjector to sit at room temperature for about 30 minutes and check that the liquid is clear to slightly yellow and free of large particles or discoloration.

Disposal

• Simponi syringes and autoinjectors are single-use only; never reuse needles or devices and do not attempt to recap needles.
• Immediately place used syringes or autoinjectors into an FDA-cleared sharps container; do not discard them loose in household trash or recycling.
• Follow your pharmacist’s, clinic’s, or local community’s instructions for disposing of a full sharps container, and always keep all injection supplies out of the reach of children and pets.